Chemistry:Carvotroline

From HandWiki

Carvotroline (INN; developmental code name WY-47791) is a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist which was under development as a potential antipsychotic but was never marketed.[1][2][3][4] It showed modest or moderate affinity for the dopamine D2 and serotonin 5-HT2 receptors and produced antipsychotic-like effects in animals.[5][3][4] The drug was being developed by Wyeth.[1] It reached phase 1 clinical trials prior to the discontinuation of its development.[1][6] Carvotroline was first described in the scientific literature by 1991.[7]

See also

References

  1. ↑ 1.0 1.1 1.2 "Carvotroline". 29 September 2011. https://adisinsight.springer.com/drugs/800001398. 
  2. ↑ "Delving into the Latest Updates on Carvotroline with Synapse". 28 February 2026. https://synapse.patsnap.com/drug/ba8b2d95d0334a7c8411184c9fc910cf. 
  3. ↑ 3.0 3.1 "Discovery of innovative small molecule therapeutics". Journal of Medicinal Chemistry 52 (1): 2–9. January 2009. doi:10.1021/jm8012823. PMID 19072120. 
  4. ↑ 4.0 4.1 "WY-47,791 HCl: Preclinical Profile of a Novel Potential Antipsychotic Agent". Clinical Neuropharmacology 15. 1992. doi:10.1097/00002826-199202001-00045. ISSN 0362-5664. 
  5. ↑ "Chapter 6. Antipsychotics". Annual Reports in Medicinal Chemistry. 27. Elsevier. 1992. pp. 49–57. doi:10.1016/s0065-7743(08)60404-2. ISBN 978-0-12-040527-5. 
  6. ↑ "Ascending Single-Dose Safety and Tolerance of WY-47,791 HCl, a Novel Potential Antipsychotic.". Clinical Neuropharmacology 15. 1992. doi:10.1097/00002826-199202001-00381. ISSN 0362-5664. 
  7. ↑ "WY-47,791. Antipsychotic.". Drugs Future 16 (11): 1008–1013. 1991. doi:10.1358/dof.1991.016.11.154510. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Carvotroline&oldid=4433354"